DOCSLIB.ORG

Pharmaceuticals Removed from Chemicals of Concern List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceuticals Removed from Chemicals of Concern List Pharmaceuticals Removed from Chemicals of Concern List Published by Maine DEP December 30, 2011 Source list last Date CAS Chemical Name Pharmaceutical reviewed Listed July 2009 50-06-6 Phenobarbital pharm Dec_2011 July 2009 50-28-2 oestradiol pharm Dec_2011 July 2009 50-35-1 Thalidomide pharm Dec_2011 July 2009 50-36-2 Cocaine pharm Dec_2011 July 2009 50-41-9 Clomiphene citrate pharm Dec_2011 July 2009 50-53-3 chlorpromazine pharm Dec_2011 July 2009 50-55-5 Reserpine pharm Dec_2011 July 2009 50-76-0 Actinomycin D pharm Dec_2011 July 2009 50-78-2 Aspirin pharm Dec_2011 July 2009 51-21-8 Fluorouracil pharm Dec_2011 July 2009 51-52-5 Propylthiouracil pharm Dec_2011 July 2009 51-64-9 dextroamphetamine pharm Dec_2011 July 2009 51-75-2 Nitrogen mustard (Mechlorethamine) pharm Dec_2011 July 2009 51-98-9 Norethisterone acetate (Norethindrone acetate) pharm Dec_2011 July 2009 52-01-7 Spironolactone pharm Dec_2011 July 2009 52-24-4 Tris(1-aziridinyl)phosphine sulfide (Thiotepa) pharm Dec_2011 July 2009 52-28-8 Codeine phosphate pharm Dec_2011 July 2009 52-67-5 Penicillamine pharm Dec_2011 July 2009 52-86-8 Haloperidol pharm Dec_2011 July 2009 53-16-7 oestron pharm Dec_2011 July 2009 54-62-6 Aminopterin pharm Dec_2011 July 2009 54-91-1 Pipobroman pharm Dec_2011 July 2009 55-86-7 Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride) pharm Dec_2011 July 2009 55-98-1 1,4-Butanediol dimethanesulfonate (Busulfan) pharm Dec_2011 July 2009 56-04-2 Methylthiouracil pharm Dec_2011 July 2009 56-53-1 diethylstilbestrol pharm Dec_2011 July 2009 56-75-7 Chloramphenicol pharm Dec_2011 July 2009 57-33-0 Pentobarbital sodium pharm Dec_2011 July 2009 57-53-4 Meprobamate pharm Dec_2011 July 2009 57-57-8 beta-Propiolactone pharm Dec_2011 July 2009 57-63-6 17-ethynylestradiol pharm Dec_2011 July 2009 57-83-0 Progesterone pharm Dec_2011 July 2009 58-18-4 Methyltestosterone pharm Dec_2011 July 2009 58-20-8 Testosterone cypionate pharm Dec_2011 July 2009 58-22-0 Testosterone and its esters pharm Dec_2011 July 2009 58-25-3 Chlordiazepoxide pharm Dec_2011 July 2009 59-05-2 Methotrexate pharm Dec_2011 July 2009 59-66-5 Acetazolamide pharm Dec_2011 July 2009 59-92-7 Levodopa pharm Dec_2011 July 2009 59-96-1 Phenoxybenzamine pharm Dec_2011 July 2009 60-54-8 Tetracycline (internal use) pharm Dec_2011 July 2009 60-56-0 Methimazole pharm Dec_2011 Pharmaceuticals Removed from Chemicals of Concern List Published by Maine DEP December 30, 2011 Source list last Date CAS Chemical Name Pharmaceutical reviewed Listed July 2009 61-57-4 Niridazole pharm Dec_2011 July 2009 62-44-2 Phenacetin pharm Dec_2011 July 2009 64-73-3 Demeclocycline hydrochloride (internal use) pharm Dec_2011 July 2009 64-75-5 Tetracycline hydrochloride (internal use) pharm Dec_2011 July 2009 64-86-8 Colchicine pharm Dec_2011 July 2009 66-75-1 Uracil mustard pharm Dec_2011 July 2009 66-76-2 Dicumarol pharm Dec_2011 July 2009 67-20-9 Nitrofurantoin pharm Dec_2011 July 2009 67-45-8 Furazolidone pharm Dec_2011 July 2009 68-22-4 Norethisterone (Norethindrone) pharm Dec_2011 July 2009 68-23-5 Norethynodrel pharm Dec_2011 July 2009 68-90-6 benziodarone pharm Dec_2011 July 2009 72-33-3 mestranol pharm Dec_2011 July 2009 76-43-7 Fluoxymesterone pharm Dec_2011 July 2009 84-17-3 Dienestrol pharm Dec_2011 July 2009 99-66-1 Valproate (Valproic acid) pharm Dec_2011 July 2009 126-85-2 Nitrogen mustard N-oxide pharm Dec_2011 July 2009 127-07-1 Hydroxyurea pharm Dec_2011 July 2009 127-48-0 Trimethadione pharm Dec_2011 July 2009 141-90-2 Thiouracil pharm Dec_2011 July 2009 143-67-9 Vinblastine sulfate pharm Dec_2011 July 2009 143-81-7 Butabarbital sodium pharm Dec_2011 July 2009 147-94-4 Cytarabine pharm Dec_2011 July 2009 148-82-3 Melphalan pharm Dec_2011 July 2009 151-67-7 Halothane pharm Dec_2011 July 2009 154-42-7 Thioguanine pharm Dec_2011 July 2009 154-93-8 Bischloroethyl nitrosourea (BCNU) (Carmustine) pharm Dec_2011 July 2009 298-46-4 Carbamazepine pharm Dec_2011 July 2009 300-62-9 amphetamine pharm Dec_2011 July 2009 302-70-5 Nitrogen mustard N-oxide hydrochloride pharm Dec_2011 July 2009 302-79-4 All-trans retinoic acid pharm Dec_2011 July 2009 305-03-3 Chlorambucil pharm Dec_2011 July 2009 309-43-3 Secobarbital sodium pharm Dec_2011 July 2009 315-37-7 Testosterone enanthate pharm Dec_2011 July 2009 320-67-2 Azacitidine pharm Dec_2011 July 2009 364-98-7 Diazoxide pharm Dec_2011 July 2009 366-70-1 Procarbazine hydrochloride pharm Dec_2011 July 2009 379-79-3 Ergotamine tartrate pharm Dec_2011 July 2009 389-08-2 Nalidixic acid pharm Dec_2011 July 2009 434-07-1 Oxymetholone pharm Dec_2011 July 2009 435-97-2 Phenprocoumon pharm Dec_2011 July 2009 438-41-5 Chlordiazepoxide hydrochloride pharm Dec_2011 Pharmaceuticals Removed from Chemicals of Concern List Published by Maine DEP December 30, 2011 Source list last Date CAS Chemical Name Pharmaceutical reviewed Listed July 2009 439-14-5 Diazepam pharm Dec_2011 July 2009 446-86-6 Azathioprine pharm Dec_2011 July 2009 474-25-9 Chenodiol pharm Dec_2011 July 2009 484-20-8 5-Methoxypsoralen with ultraviolet A therapy pharm Dec_2011 July 2009 505-60-2 Mustard Gas pharm Dec_2011 July 2009 531-76-0 Merphalan pharm Dec_2011 July 2009 531-86-2 benzidine sulfate pharm Dec_2011 July 2009 536-33-4 Ethionamide pharm Dec_2011 July 2009 537-46-2 methamphetamine pharm Dec_2011 July 2009 564-25-0 Doxycycline (internal use) pharm Dec_2011 July 2009 590-96-5 Methylazoxymethanol pharm Dec_2011 July 2009 595-33-5 Megestrol acetate pharm Dec_2011 July 2009 604-75-1 Oxazepam pharm Dec_2011 July 2009 630-93-3 Diphenylhydantoin (Phenytoin), sodium salt pharm Dec_2011 July 2009 637-07-0 Clofibrate pharm Dec_2011 July 2009 645-05-6 Altretamine pharm Dec_2011 July 2009 665-66-7 Amantadine hydrochloride pharm Dec_2011 July 2009 671-16-9 Procarbazine pharm Dec_2011 July 2009 749-13-3 trifluperidol pharm Dec_2011 July 2009 797-63-7 Levonorgestrel implants pharm Dec_2011 July 2009 846-49-1 Lorazepam pharm Dec_2011 July 2009 846-50-4 Temazepam pharm Dec_2011 July 2009 919-16-4 Lithium citrate pharm Dec_2011 July 2009 1172-18-5 Flurazepam hydrochloride pharm Dec_2011 July 2009 1405-10-3 Neomycin sulfate (internal use) pharm Dec_2011 July 2009 1620-21-9 Chlorcyclizine hydrochloride pharm Dec_2011 July 2009 2062-78-4 pimozide pharm Dec_2011 July 2009 2068-78-2 Vincristine sulfate pharm Dec_2011 July 2009 3546-10-9 Phenesterin pharm Dec_2011 July 2009 3771-19-5 Nafenopin pharm Dec_2011 July 2009 3963-95-9 Methacycline hydrochloride pharm Dec_2011 July 2009 4291-63-8 Cladribine pharm Dec_2011 July 2009 4342-03-4 Dacarbazine pharm Dec_2011 July 2009 4394-00-7 niflumic acid pharm Dec_2011 July 2009 4759-48-2 Isotretinoin pharm Dec_2011 July 2009 5104-49-4 Flurbiprofen pharm Dec_2011 July 2009 5534-09-8 Beclomethasone dipropionate pharm Dec_2011 July 2009 6055-19-2 Cyclophosphamide (hydrated) pharm Dec_2011 July 2009 6112-76-1 Mercaptopurine pharm Dec_2011 July 2009 6190-39-2 Dihydroergotamine mesylate pharm Dec_2011 July 2009 6533-00-2 Norgestrel pharm Dec_2011 July 2009 7632-10-2 methamphetamine pharm Dec_2011 Pharmaceuticals Removed from Chemicals of Concern List Published by Maine DEP December 30, 2011 Source list last Date CAS Chemical Name Pharmaceutical reviewed Listed July 2009 9002-68-0 Menotropins pharm Dec_2011 July 2009 10043-66-0 Iodine-131 pharm Dec_2011 July 2009 10418-03-8 Stanozolol pharm Dec_2011 July 2009 10540-29-1 Tamoxifen and its salts pharm Dec_2011 July 2009 13292-46-1 Rifampin pharm Dec_2011 July 2009 13311-84-7 Flutamide pharm Dec_2011 July 2009 13614-98-7 Minocycline hydrochloride (internal use) pharm Dec_2011 July 2009 13647-35-3 Trilostane pharm Dec_2011 July 2009 14028-44-5 Amoxapine pharm Dec_2011 July 2009 15475-56-6 Methotrexate sodium pharm Dec_2011 July 2009 15663-27-1 Cisplatin pharm Dec_2011 July 2009 17086-28-1 Doxycycline monohydrate (internal use) pharm Dec_2011 July 2009 17230-88-5 Danazol pharm Dec_2011 July 2009 18378-89-7 Plicamycin pharm Dec_2011 July 2009 21739-91-3 Cytembena pharm Dec_2011 July 2009 21829-25-4 Nifedipine pharm Dec_2011 July 2009 22494-42-4 Diflunisal pharm Dec_2011 July 2009 23092-17-3 Halazepam pharm Dec_2011 July 2009 23214-92-8 Adriamycin pharm Dec_2011 July 2009 23593-75-1 clotrimazole pharm Dec_2011 July 2009 24390-14-5 Doxycycline hyclate (internal use) pharm Dec_2011 July 2009 25122-46-7 Clobetasol propionate pharm Dec_2011 July 2009 25316-40-9 Doxorubicin hydrochloride (Adriamycin) pharm Dec_2011 July 2009 25812-30-0 Gemfibrozil pharm Dec_2011 July 2009 29122-68-7 Atenolol pharm Dec_2011 July 2009 29767-20-2 Teniposide pharm Dec_2011 July 2009 31431-39-7 Mebendazole pharm Dec_2011 July 2009 33069-62-4 Paclitaxel pharm Dec_2011 July 2009 33286-22-5 Diltiazem hydrochloride pharm Dec_2011 July 2009 33419-42-0 Etoposide pharm Dec_2011 July 2009 34031-32-8 Auranofin pharm Dec_2011 July 2009 36735-22-5 Quazepam pharm Dec_2011 July 2009 36791-04-5 Ribavirin pharm Dec_2011 July 2009 38194-50-2 Sulindac pharm Dec_2011 July 2009 38260-01-4 Trientine hydrochloride pharm Dec_2011 July 2009 39831-55-5 Amikacin sulfate pharm Dec_2011 July 2009 41340-25-4 Etodolac pharm Dec_2011 July 2009 41575-94-4 Carboplatin pharm Dec_2011 July 2009 49842-07-1 Tobramycin sulfate pharm Dec_2011 July 2009 52468-60-7 sibelium pharm Dec_2011 July 2009 53910-25-1 Pentostatin pharm Dec_2011 July 2009 54350-48-0 Etretinate pharm Dec_2011 Pharmaceuticals Removed from Chemicals of Concern List Published by Maine DEP December 30, 2011 Source list last Date CAS Chemical Name Pharmaceutical reviewed Listed July 2009 54749-90-5 Chlorozotocin pharm Dec_2011 July 2009
Load more

Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • California Proposition 65 Toxicity List
    STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986 CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY 4-Mar-05 The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and Chemical Type of Toxicity CAS No. Date Listed A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) cancer 26148685 1-Jan-90 Acetaldehyde cancer 75070 1-Apr-88 Acetamide cancer 60355 1-Jan-90 Acetazolamide developmental 59665 20-Aug-99 Acetochlor cancer 34256821 1-Jan-89 Acetohydroxamic acid developmental 546883 1-Apr-90 2-Acetylaminofluorene cancer 53963 1-Jul-87 Acifluorfen cancer 62476599 1-Jan-90 Acrylamide cancer 79061 1-Jan-90 Acrylonitrile cancer 107131 1-Jul-87 Actinomycin D cancer 50760 1-Oct-89 Actinomycin D developmental 50760 1-Oct-92 Adriamycin (Doxorubicin hydrochloride) cancer 23214928 1-Jul-87 AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide cancer 3688537 1-Jul-87 Aflatoxins cancer --- 1-Jan-88 Alachlor cancer 15972608 1-Jan-89 Alcoholic beverages, when associated with alcohol abuse cancer --- 1-Jul-88 Aldrin cancer 309002 1-Jul-88 All-trans retinoic acid developmental 302794 1-Jan-89 Allyl chloride Delisted October 29, 1999 cancer 107051 1-Jan-90 Alprazolam developmental 28981977 1-Jul-90 Altretamine developmental, male 645056 20-Aug-99 Amantadine hydrochloride developmental 665667 27-Feb-01 Amikacin sulfate developmental 39831555 1-Jul-90 2-Aminoanthraquinone cancer 117793 1-Oct-89 p -Aminoazobenzene cancer
    [Show full text]
  • Postmenopausal Pharmacotherapy Newsletter
    POSTMENOPAUSAL PHARMACOTHERAPY September, 1999 As Canada's baby boomers age, more and more women will face the option of Hormone Replacement Therapy (HRT). The HIGHLIGHTS decision can be a difficult one given the conflicting pros and cons. M This RxFiles examines the role and use of HRT, as well as newer Long term HRT carries several major benefits but also risks SERMS and bisphosphonates in post-menopausal (PM) patients. which should be evaluated on an individual and ongoing basis MContinuous ERT is appropriate for women without a uterus HRT MWomen with a uterus should receive progestagen (at least 12 HRT is indicated for the treatment of PM symptoms such as days per month or continuous low-dose) as part of their HRT vasomotor disturbances and urogenital atrophy, and is considered MLow-dose ERT (CEE 0.3mg) + Ca++ appears to prevent PMO primary therapy for prevention and treatment of postmenopausal MBisphosphinates (e.g. alendronate, etidronate) and raloxifene are osteoporosis (PMO).1 Contraindications are reviewed in Table 2. alternatives to HRT in treating and preventing PMO Although HRT is contraindicated in women with active breast or M"Natural" HRT regimens can be compounded but data is lacking uterine cancer, note that a prior or positive family history of these does not necessarily preclude women from receiving HRT.1 Comparative Safety: Because of differences between products, some side effects may be alleviated by switching from one product Estrogen Replacement Therapy (ERT) 2 to another, particularly from equine to plant sources or from oral to Naturally secreted estrogens include: topical (see Table 3 - Side Effects & Their Management).
    [Show full text]
  • COMBINED LIST of Particularly Hazardous Substances
    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
    [Show full text]
  • Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1
    Organic Chemistry I Laboratory Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1 Background Reading Zubrick, J. W. The Organic Chem Lab Survival Manual, 4th edition, Wiley & Sons, Inc., New York, 1997. Keeping a Notebook: Pg 12-24. Interpreting Handbooks: Pg 26-31, 34-44. Extraction and Washing: Pg 148-168. Background Senario One of the many places organic chemists are employed is in private laboratories associated with consulting firms. The purpose of these labs is generally to provide chemical analysis or synthesis of material for customers. The first few labs in CHM 220 will teach you the basic techniques needed to analyze and purify mixtures to determine the individual components. This first lab will involve determining the composition of a possible pharmaceutical preparation. Watchdog agencies exist which monitor the pharmaceuticals sold over the counter in the United States. These agencies will use private laboratory firms to analyze products suspected of violating enforced standards. For example, a new brand of analgesic may appear on drugstore shelves at a low price. The label indicates that the tablets were manufactured in the United States by a legitimate pharmaceutical company. However, the labels may reveal discrepancies and the appearance/quality of the tablets could lead an investigator to suspect that they might be counterfeit. Such knockoffs of a domestic product can be manufactured cheaply elsewhere and smuggled into the US, where they are sold for high profits. This laboratory exercise places you in the position of analyzing a suspected counterfeit analgesic preparation. The label on the suspected bottle lists the ingredients per tablet as aspirin (200 mg), acetaminophen (250 mg), and sucrose (50 mg).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).
    [Show full text]
  • Download Our Summer 2010 Newsletter
    A n e w s l e t t e r f o r r e f e r r i n g veterinarians JOIN US IN 2011 AS WE CELEBRATE METROPOLITAN VETERINARY ASSOCIATES 25 P roviding emergency care & specialized veterinary services YEARS INSID E: p2-3 WELCOME TO Trilostane for the Treatment of Canine the fourth edition of our newsletter Hyperadrenocorticism – The Answer to Our Problems? Established in 1986, Metropolitan Veterinary Associates & Emergency Services p4 is a veterinary group that provides referral veterinary services. We concentrate Pet Loss Support Group & Monthly Lecture Series on specialty and emergency cases, allowing us to dedicate high-level care to the following disciplines: behavior, cardiology, dentistry, dermatology, I NSERT: emergency, internal medicine, neurology, ophthalmology, radiology front (including CT and MRI) and surgery. Meet our internal medicine team In order to maintain a high level of patient care, MVA moved into a newly back renovated 18,000 square foot facility with state-of-the-art diagnostic and Join us for CE therapeutic equipment in 2006. If you haven’t been able to visit our practice, we hope you can join us at one of the upcoming hospital lectures mentioned on page 4. Please enjoy this newsletter and let us know of any topics of interest you’d like to see explored in future editions. We’ve made it easier to contact us. Catch us 24 HOURS A DAY at 610/666/1050! (our primary phone number) DID YOU KNOW? TRILOSTANE FOR THE TREATMENT OF ! CANINE HYPERADRENOCORTICISM – THE ANSWER TO OUR PROBLEMS? By: Damon B.
    [Show full text]
  • Chemical Muscle Enhancement (The BDR) by Author L
    Chemical Muscle Enhancement (The BDR) By Author L. Rea TABLE OF CONTENTS 1. AAS INTRODUCTION ..PG’S 1-12 WARNING: READ FIRST OVER 20 YEARS AGO... WHY STEROIDS AND WHAT IS POSSIBLE? WHAT ARE STEROIDS? FEMALE HORMONE SYNTHESIS MALE HORMONE SYNTHESIS TESTOSTERONE... WHAT DOES IT DO? STEROIDS INCREASE PC SYNTHESIS STEROIDS EFFECT BLOOD VOLUME WHAT HAPPENS AFTER TESTOSTERONE MOLECULES LEAVE RECEPTORS? STEROIDS...GROWTH ON THE CELULAR LEVEL 2. DRUG REFERENCES AND DESCRIPTIONS..PG 12 ORAL ANABOLIC / ANDROGENIC STEROIDS..PG’S 13-30 INJECTABLE ANABOLIC / ANDROGENIC STEROIDS..PG’S 31-45 TESTOSTERONE AND ITS ESTERS..PG’S 45-61 NORTESTOSTERONE (NANDROLONE) AND ITS ESTER..PG’S 62-70 TRENBOLONE AND DERIVATIVES..PG’S 71-78 ESTROGEN CONTROL AND HPTA REGENERATION DRUGS..PG’S 79-94 DIURETICS..PG’S 95-102 THYROID HORMONES ..PG’S 103-116 NON-AAS GROWTH FACTORS AND RELATED SUBSTANCES..PG’S 117-141 OTHER SUBSTANCES..PG’S 142-152 3. REPORTED CYCLES AND EFFECTS.. (Introduction) PG’S 153-159 REPORTED CYCLES AND EFFECTS EXAMPLES (MALE)...PG’S 160-169 REPORTED CYCLES AND EFFECTS EXAMPLES (FEMALE)...PG’S 170-174 REPORTED ADVANCED CYCLES AND EFFECTS-BLITZ CYCLES..PG’S 175-200 (More Reported Cycles and Effects) 4. NUTRITION..PG’S..201-211 5. SUPPLEMENTAL CREATINE..PG’S 212-216 6. REFERENCES AND AVAILABLE LITERATURE..PG’S 217-223 All Rights Reserved CHEMICAL MUSCLE ENHANCEMENT (The Report) and BODYBUILDERS DESK REFERENCE COPYRIGHT ©2002 by AUTHOR L. REA No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopy, recording, or by any information storage and retrieval system, without the permission in writing of the author and publisher.
    [Show full text]
  • Hormone Replacement Therapy and Osteoporosis
    This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting.
    [Show full text]
  • Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System S
    Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Tsamandouras, N., T. Kostrzewski, C. L. Stokes, L. G. Griffith, D. J. Hughes, and M. Cirit. “Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System.” Journal of Pharmacology and Experimental Therapeutics 360, no. 1 (October 19, 2016): 95–105. As Published http://dx.doi.org/10.1124/JPET.116.237495 Publisher American Society for Pharmacology & Experimental Therapeutics (ASPET) Version Final published version Citable link http://hdl.handle.net/1721.1/117617 Terms of Use Creative Commons Attribution-NonCommercial 4.0 International Detailed Terms http://creativecommons.org/licenses/by-nc/4.0/ Downloaded from jpet.aspetjournals.org at ASPET Journals on August 30, 2018 95 105, January 2017 – and the associ- ” http://dx.doi.org/10.1124/jpet.116.237495 c clearance, as assessed in vitro, g metabolism in the context of a J Pharmacol Exp Ther 360:95 average individual, “ Several in vitro systems have been traditionally applied to ated interindividual variability is not obtained. variability in intrinsic metaboli needstobecoupledwiththepopulationvariabilityassociated with other physiologic processes indrug vivo binding (e.g., to hepatic plasma bloodpredictions proteins, flow, etc.). at Thus, to theapproach perform population (Trame in vivo et level,results al., a are 2016) integrated systems is into pharmacology desirable,pharmacokinetic population physiologically (PBPK) where based models the (Rostami-Hodjegan, inJones and 2012; vitro Rowland-Yeo, 2013; Tsamandouras et al., 2015a,b).
    [Show full text]